Market Movers, May.29th

AMRN receives FDA supplemental new drug Application, up 7% on 120k shares traded in the premarket. “Vascepa, assuming approval, will be first drug indicated to reduce residual cardiovascular risk in patients with statin-managed LDL-C cholesterol” Read more…

Soliton, Inc. following through after receiving FDA 510(k) Clearance of its Acoustic Shockwave RAP Device yesterday. 334750 shares traded so far in the premarket

Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus . Currently up 16% on 65 000 shares traded

GOOS down 15% after reporting yearly earnings. 113490 shares traded in the premarket. Net income was $143.6m, or $1.28 per diluted share, beating consensus estimates by 30 cents. Some highlights from the report below

Abercrombie & Fitch Co reports same-store sales that missed expectations, weak guidance. Down 17%, Tonya Garcia of Market Watch reports

ELTK up 75% in the premarket on 500k shares traded

69% shareholder

Dow futures pointing to 174-point decline as yields keep falling, CNBC reports

Yields on the 10 year note inverted lower then the 3 month t-bill , the widest inversion since the financial crisis. The spread between the 2 and the 10 is currently only 15 basis points

ELTK reported net tangible book value of $1.14 after their most recent stock offering on March.18, 2019

Dow drops more than 250 points, CNBC reports, 11:35am

Dow Jones Industrial Average down -323.07 (-1.27%) 12:52pm

Supply disruptions outweighed by trade war worries, oil down 0.6% , CNBC

Leave a Reply